Inventor · disambiguated record
John Buell
Also filed as: BUELL JOHN
15 granted patents·3 pending applications·108 citations·filing 2013–2024
91Inventor score
Top patents by PatentIndex Score
18 records- 0197US9771369B2Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2015·Granted Sep 26, 2017·24 cites·18 claims
- 0295US9718847B2Heterocyclic compounds and uses thereofPLEXXIKON INC·Filed 2014·Granted Aug 1, 2017·33 cites·21 claims
- 0394US10160755B2Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2016·Granted Dec 25, 2018·15 cites·14 claims
- 0491US11739101B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·3 cites·40 claims
- 0588US10703757B2Compounds and methods for CDK8 modulation and indications thereforPLEXXIKON INC·Filed 2017·Granted Jul 7, 2020·4 cites·38 claims
- 0687US10160747B2Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2017·Granted Dec 25, 2018·8 cites·25 claims
- 0785US10508085B2Compounds and methods for IDO and TDO modulation, and indications thereforPLEXXIKON INC·Filed 2017·Granted Dec 17, 2019·6 cites·37 claims
- 0884US10519177B2Heterocyclic compounds and uses thereofPLEXXIKON INC·Filed 2017·Granted Dec 31, 2019·4 cites·22 claims
- 0984US10227357B2Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2013·Granted Mar 12, 2019·7 cites·7 claims
- 1083US11807626B2Compounds and methods for CD73 modulation and indications thereforOpna Bio SA·Filed 2021·Granted Nov 7, 2023·1 cites·40 claims
- 1180US11149011B2Compounds and methods for IDO and TDO modulation, and indications thereforPLEXXIKON INC·Filed 2019·Granted Oct 19, 2021·2 cites·23 claims
- 1273US12202818B2Compounds and methods for CD73 modulation and indications thereforOpna Bio SA·Filed 2023·Granted Jan 21, 2025·0 cites·31 claims
- 1373US2024400587A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1472US11446287B2Compounds and methods for EP300 or CBP modulation and indications thereforOPNA IMMUNO ONCOLOGY SA·Filed 2020·Granted Sep 20, 2022·1 cites·37 claims
- 1568US12091426B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Sep 17, 2024·0 cites·29 claims
- 1667US2024025923A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1755US2023081426A1Compounds and methods for kras modulation and indications thereforPLEXXIKON INC·Filed 2021·Application pending·0 cites
- 1850US12509444B2Compounds and methods for CD73 modulation and indications thereforPLEXXIKON INC·Filed 2020·Granted Dec 30, 2025·0 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →